Question-and-Answer Session
Operator
(Operator Instructions) Our first question comes Roopesh Patel with UBS please go ahead.
Roopesh Patel - UBS
Thank you. I have a couple of questions, first on Cymbalta. In light of the recent slowdown in market share trends over the past five months, I was just wondering, John if you expect any meaningful change in trends as you look forward, and if so what's going to spark that? And then just separately I was just wondering if you could update us on your patient assistance program. I am curious on what level the current enrollment has reached relative to levels before this program was stopped before 2006. And how much further enrollment you expect and what sort of impact that might have looking forward, specifically on Zyprexa and Forteo? Thanks.
John Lechleiter
Roopesh this is John. I will answer your first question, and then maybe refer to Phil or Jim on the patient assistant question. First of all, as we indicated in the context, we continue to be pleased with the performance of Cymbalta, because we do see share growth and that’s really what we are focused on, and we also know we have got three, really three of our largest OUS markets yet to launch the product. We have another indication that's under review by the FDA right now, which is fibromyalgia, and we seen Lyrica do well in that space. We are competing successfully today against Lyrica and the DPMP indication, so that, obviously if approved, is going to provide another avenue for growth.
Cymbalta continues, really to perform very well in terms of the acceptance by physicians and patients. Keep in mind that we have also started a new DCCC campaign, built along the same theme. The depression hurt scene that's been out there for couple of seasons now. So, I think this is going to continue also to really support the product and to keep it, a significant contributor to our growth going forward.
Phil Johnson
Yeah, this is Phil. Second question you had. We continue to see a relatively slow ramp up of enrollments in the current programs, which as you are aware covers HGH, Zyprexa and Forteo. Forteo is the product that is getting the most usage, but we are at levels that would be a very small portion of the levels that we had last year.
Roopesh Patel - UBS
And just if I may follow up, do you expect that enrollment to get back to original status, and if so is there any material impact you might see that have on either Zyprexa or Forteo?
- To read the full transcript on Seeking Alpha, click here »
